MESO · Mesoblast Ltd ADR
United States · RS rating 17 · As of 2026-10-14
| Price | 13.79 USD |
|---|---|
| 1-day change | -0.8% |
| RS rating (overall / 1M / 3M / 12M) | 17 / 32 / 17 / 24 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 25 / 7 / 17 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | – |
| Distance from 52-week high | +34.2% |
| Market cap (USD) | $2.0B |